2022, 4+, Analisi statistiche e metanalisi, Autore, Cancanelli, Chiumente, Di Spazio, Impact factor, Mengato, Messori, Pubblicazioni, Rivano, Topic
Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials.
1-2, 2022, Analisi statistiche e metanalisi, Autore, Cancanelli, Chiumente, Damuzzo, Impact factor, Mengato, Messori, Ossato, Pubblicazioni, Rivano, Topic
The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma.
0-1, 2022, Analisi statistiche e metanalisi, Autore, Cancanelli, Chiumente, Di Spazio, Impact factor, Mengato, Messori, Pubblicazioni, Rivano, Topic
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy
1-2, 2022, Analisi statistiche e metanalisi, Anno, Autore, Cancanelli, Chiumente, Di Spazio, Impact factor, Mengato, Messori, Pubblicazioni, Rivano, Topic
The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors.
1-2, 2021, Analisi statistiche e metanalisi, Anno, Autore, Cancanelli, Chiumente, Di Spazio, Impact factor, Mengato, Messori, Pubblicazioni, Rivano, Topic
Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials.
1-2, 2021, Agnoletto, Anno, Autore, Cammalleri, Cancanelli, Chiumente, Costantino, Damuzzo, Impact factor, Mengato, Michielan, Milani, Pubblicazioni, Rampazzo, Rivano, Sartori, Studi real world, Topic